clinical trial · NCT03163511
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
ViaCyte·phase2·completed·n = 49
Type 1 Diabetes Mellitus With HypoglycemiaVC-02 Combination Product
brief summary
VC02-101 will evaluate an experimental cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes and Hypoglycemia Unawareness.
started
Jul 6, 2017
primary completion
Oct 13, 2023
completion
Oct 19, 2023
last updated
Dec 3, 2024
detailed description
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and Hypoglycemia Unawareness and maintained safely for up to two years. It will also test if VC-02 is an effective treatment for these subjects.
official title
An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol